Golimumab for the treatment of axial spondyloarthritis

References

• Rudwaleit M, van der Heijde D, Landewé R, et al. The development of assessment of spondyloarthritis international society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68:777–783. DOI:10.1136/ard.2009.108233.
   PubMed Web of Science ®Google Scholar
• Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum. 1984;27:361–368.
   PubMed Web of Science ®Google Scholar
• Poddubnyy D, Haibel H, Braun J, et al. Brief report: clinical course over two years in patients with early nonradiographic axial spondyloarthritis and patients with ankylosing spondylitis not treated with tumor necrosis factor blockers: results from the German spondyloarthritis inception cohort. Arthritis Rheumatol. 2015;67:2369–2375. DOI:10.1002/art.39225.
   PubMed Web of Science ®Google Scholar
• Braun J, van den Berg R, Baraliakos X, et al. update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 2010;2011(70):896–904.
   Google Scholar
• Callhoff J, Sieper J, Weiß A, et al. Efficacy of TNFα blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis. Ann Rheum Dis. 2015;74:1241–1248. DOI:10.1136/annrheumdis-2014-205322
   PubMed Web of Science ®Google Scholar
• Lubrano E, Perrotta FM, Marchesoni A, et al. Remission in nonradiographic axial spondyloarthritis treated with anti-tumor necrosis factor-α drugs: an Italian multicenter study. J Rheumatol. 2015;42:258–263. DOI:10.3899/jrheum.140811.
   PubMed Web of Science ®Google Scholar
• Ciurea A, Weber U, Stekhoven D. Treatment with tumor necrosis factor inhibitors in axial spondyloarthritis: comparison between private rheumatology practices and academic centers in a large observational cohort. J Rheumatol. 2015;42:101–105. DOI:10.3899/jrheum.140229.
   PubMed Web of Science ®Google Scholar
• Chen JS, Makovey J, Lassere M, et al. Comparative effectiveness of anti-tumour necrosis factor (TNF) drugs on health-related quality of life among patients with inflammatory arthritis. Arthritis Care Res (Hoboken). 2014;66:464–472. DOI:10.1002/acr.22151.
   PubMed Web of Science ®Google Scholar
• Shu T, Chen GH, Rong L, et al. Indirect comparison of anti-TNF-alpha agents for active ankylosing spondylitis: mixed treatment comparison of randomized controlled trials. Clin Exp Rheumatol. 2013;31:717–722.
   PubMed Web of Science ®Google Scholar
• Migliore A, Broccoli S, Bizzi E, et al. Indirect comparison of the effects of anti-TNF biological agents patients with ankylosing spondylitis means of a mixed treatment comparison performed on efficacy data from published randomised, controlled trials. J Med Econ. 2012;15:473–480. DOI:10.3111/13696998.2012.660255.
   PubMedGoogle Scholar
• van der Heijde D, Salonen D, Weissman BN, et al. Canadian (M03-606) study group; ATLAS study group. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res Ther. 2009;11:R127.
   Web of Science ®Google Scholar
• van der Heijde D, Landewé R, Baraliakos X, et al. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum. 2008 Oct;58(10):3063–3070. DOI:10.1002/art.23901.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Landewé R, Einstein S, et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum. 2008;58:1324–1331. DOI:10.1002/art.23471.
   PubMed Web of Science ®Google Scholar
• Baraliakos X, Haibel H, Listing J, et al. Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis. Ann Rheum Dis. 2014;73:710–715. DOI:10.1136/annrheumdis-2012-202698.
   PubMed Web of Science ®Google Scholar
• Braun J, Baraliakos X, Hermann KG, et al. The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial. Ann Rheum Dis. 2014;73:1107–1113. DOI:10.1136/annrheumdis-2012-203075
   PubMed Web of Science ®Google Scholar
• Haroon N, Inman RD, Laerch TJ, et al. The impact of tumor necrosis factor α inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum. 2013;65:2645–2654. DOI:10.1002/art.38070
   PubMed Web of Science ®Google Scholar
• Shealy DJ, Cai A, Staquer T, et al. Characterization of golimumab, a human monoclomnal antibody specific for human tumor necrosis factor alpha. Mabs. 2010;2:428–439.
   PubMed Web of Science ®Google Scholar
• Xu Z, Wang Q, Zhuang Y, et al. Subcutaneous bioavailability of golimumab at 3 different injection sites in healthy subjects. J Clin Pharmacol. 2010;50:276–284. DOI:10.1177/0091270009340782.
   PubMed Web of Science ®Google Scholar
• Zhou H, Jang H, Fleishmann RM, et al. Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis. J Clin Pharmacol. 2007;47:383–396. DOI:10.1177/0091270006298188.
   PubMed Web of Science ®Google Scholar
• Sieper J, Van Der Heijde D, Dougados M, et al. A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis. Arthritis Rheumatol. 2015;67:2702–2712. DOI:10.1002/art.39257
   PubMed Web of Science ®Google Scholar
• Inman RD, Davies JC Jr, van der Heijde D, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double blind, placebo-controlled, phase III trial. Arthritis Rheum. 2008;58:3402–3412. DOI:10.1002/art.23969
   PubMed Web of Science ®Google Scholar
• Braun J, Deodhar A, Inman RD, et al. Golimumab administered subcutaneously every 4 weeks, in ankylosing spondylitis: 104-week results of the GO-RAISE study. Ann Rheum Dis. 2012;71:661–667. DOI:10.1136/ard.2011.154799.
   PubMed Web of Science ®Google Scholar
• Deodhar A, Braun J, Inman RD, et al. Golimumab administered subcutaneously every 4 weeks, in ankylosing spondylitis: 5-year results of the GO-RAISE study. Ann Rheum Dis. 2015;74:757–761. DOI:10.1136/annrheumdis-2014-205862
   PubMed Web of Science ®Google Scholar
• Bao C, Huang F, Khan MA, et al. Safety and efficacy of golimumab in Chinese patients with active ankylosing spondylitis: 1-year results of a multicentere, randomized, double blind, placebo-controlled phase III trial. Rheumatology (Oxford). 2014;53:1654–1663. DOI:10.1093/rheumatology/keu132.
   PubMed Web of Science ®Google Scholar
• Moc CC, Li C, Chan KL, et al. Effect of golimumab and pamidronate on clinical efficacy and MRI inflammation in axial spondyloarthritis: a 48-week open randomized trial. Scand J Rheumatol. 2015;44:480–486. DOI:10.3109/03009742.2015.1038300.
   PubMed Web of Science ®Google Scholar
• Toussirot E, Wendling D. Bisphosphonates as anti-inflammatory agents in ankylosing spondylitis and spondylarthropathies. Expert Opin Pharmacother. 2005;6:35–43. DOI:10.1517/14656566.6.1.35.
   PubMed Web of Science ®Google Scholar
• Van Tubergen A, Ramiro S, Van Der Heijde D, et al. Development of new syndesmophytes and bridges in ankylosing spondylitis and their predictors: a longitudinal study. Ann Rheum Dis. 2012;71:518–523. DOI:10.1136/annrheumdis-2011-200411.
   PubMed Web of Science ®Google Scholar
• Ramiro S, Van Der Heijde D, Van Tubergen A, et al. Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort. Ann Rheum Dis. 2014;73:1455–1461. DOI:10.1136/annrheumdis-2014-205178.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Dougados M, Maksymowych W, et al. Long-term tolerability and efficacy of golimumab in active nonradiographic axial spondyloarthritis: results from the open-label extension of a randomized, double-blind study. 2015 ACR-ARHP annual meeting. Abstract # 2854.
   Google Scholar